OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference

BusinesswireDec 17 05:15

OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates

Simply Wall StNov 15 22:26

Benchmark Co. Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $8

Futu NewsNov 14 21:31 · Ratings

A Quick Look at Today's Ratings for OmniAb(OABI.US), With a Forecast Between $8 to $11

Futu NewsNov 14 21:00 · Ratings

OmniAb Analyst Ratings

BenzingaNov 14 18:53 · Ratings

OmniAb's Robust Pipeline and Strategic Positioning Drive Buy Rating Despite Macroeconomic Challenges

TipRanksNov 14 15:39 · Ratings